Background Interferon γ (IFNγ) is considered a seminal cytokine in the pathogenesis of giant cell arteritis (GCA), but its functional role has not been investigated. We explored changes in infiltrating cells and biomarkers elicited by blocking IFNγ with a neutralising monoclonal antibody, A6, in temporal arteries from patients with GCA.
Methods Temporal arteries from 34 patients with GCA (positive histology) and 21 controls were cultured on 3D matrix (Matrigel) and exposed to A6 or recombinant IFNγ. Changes in gene/protein expression were measured by qRT-PCR/western blot or immunoassay. Changes in infiltrating cells were assessed by immunohistochemistry/immunofluorescence. Chemotaxis/adhesion assays were performed with temporal artery-derived vascular smooth muscle cells (VSMCs) and peripheral blood mononuclear cells (PBMCs).
Results Blocking endogenous IFNγ with A6 abrogated STAT-1 phosphorylation in cultured GCA arteries. Furthermore, selective reduction in CXCL9, CXCL10 and CXCL11 chemokine expression was observed along with reduction in infiltrating CD68 macrophages. Adding IFNγ elicited consistent opposite effects. IFNγ induced CXCL9, CXCL10, CXCL11, CCL2 and intracellular adhesion molecule-1 expression by cultured VSMC, resulting in increased PBMC chemotaxis/adhesion. Spontaneous expression of chemokines was higher in VSMC isolated from GCA-involved arteries than in those obtained from controls. Incubation of IFNγ-treated control arteries with PBMC resulted in adhesion/infiltration by CD68 macrophages, which did not occur in untreated arteries.
Conclusions Our ex vivo system suggests that IFNγ may play an important role in the recruitment of macrophages in GCA by inducing production of specific chemokines and adhesion molecules. Vascular wall components (ie, VSMC) are mediators of these functions and may facilitate progression of inflammatory infiltrates through the vessel wall.
- Giant Cell Arteritis
- Systemic vasculitis
Statistics from Altmetric.com
Giant cell arteritis (GCA) is a chronic inflammatory disease targeting large and medium-sized arteries in aged individuals.1 In spite of the initial response to high-dose glucocorticoids (GCs), 40–60% of patients relapse when GCs are tapered and prolonged GC treatment results in significant side effects.2
Search for new therapeutic options requires better understanding of pathogenesis. GCA has been classically considered a Th1-mediated disease based on the granulomatous nature of inflammatory lesions with the presence of giant cells.1 ,3 Moreover, while transcripts of several cytokines (ie, interleukin (IL)-6, tumour necrosis factor-α (TNFα) can be detected in unaffected temporal artery biopsies (TABs),4–7 IFNγ, the distinctive cytokine produced by Th1 lymphocytes, is selectively expressed in GCA lesions.4 ,7–12 Recently, Th17-mediated mechanisms are also emerging as a relevant component of GCA pathogenesis.9–13
IFNγ has important roles in innate and adaptive immunity. It is primarily expressed by Th1 and natural killer (NK) cells and also by plasmacytoid dendritic cells, B cells and macrophages.14 ,15 IFNγ signals by inducing dimerisation of its receptor chains, which, in turn, induces phosphorylation of JAK 1 and JAK 2, creating binding sites for STAT-1.14 ,16 ,17 STAT-1 phosphorylation results in STAT-1 dimerisation or formation of multimolecular complexes (ie, ISFG3 composed by STAT-1, STAT-2 and IRF9 molecules) subsequently inducing transcription of genes bearing gamma-activated sequences or interferon-stimulated responsive elements (ISREs), respectively, in their promoter regions.14 ,16 ,17 Some of the STAT-1-induced target genes are themselves transcription factors (ie, IRFs), creating subsequent waves of inflammatory molecule expression.18 Adding complexity, IFNγ may also induce STAT-3, particularly in conditions of STAT-1 paucity.19 IFNγ promotes NK cell activity, macrophage activation, Th1 differentiation and expression of class I and class II major histocompatibility complex molecules on antigen-presenting cells.14–21 Based on these functions, IFNγ is thought to have a major role in GCA. Its expression by adventitial infiltrates in early GCA lesions suggests a relevant role from the initial steps of vascular inflammation.11 ,22
To date, no mechanistic studies assessing the role of IFNγ in the development of full-blown lesions in GCA have been performed. In this study, we explored functional roles of IFNγ on GCA lesions by exposing cultured temporal artery sections from patients with GCA to a neutralising anti-human IFNγ monoclonal antibody.
Patients and methods
TABs were performed to 55 patients with suspected GCA for diagnostic purposes. A 5–15 mm segment was saved for the present study. Thirty-four patients had histopathological features of GCA in their TAB. Thirteen of them had started GC treatment 3.6±3.2 days before TAB. Twenty-one patients had no inflammatory infiltrates and served as controls. Clinical data of GCA patients and final diagnosis in control patients are disclosed in online supplementary tables S1 and S2, respectively.
Neutralising, monoclonal antibody A6 against IFNγ
A6 is a fully human monoclonal antibody generated in the laboratories of Novimmune (Geneva, Switzerland) from human immunoglobulin libraries using in vitro display technologies. A6 binds to human IFNγ and neutralises its bioactivity.
Temporal artery culture
Temporal artery sections from patients with GCA and controls were embedded in Matrigel to ensure prolonged survival, cultured ex vivo as described7 with or without A6 antibody (10 μg/mL), recombinant IFNγ at 100 ng/mL (R&D Systems, Minneapolis, Minnesota, USA), human non-immune immunoglobulin IgG1 at 10 μg/mL (Sigma, Ayrshire, UK) as a negative control or dexamethasone (0.5 μg/mL, Sigma). Each condition was tested in 3–4 replicate wells. Biopsies were frozen in TRIzol reagent (Life Technologies) for RNA extraction or in radioimmunoprecipitation assay buffer with protease and phosphatase inhibitors for western blot studies.
Vascular smooth muscle cells (VSMCs) were isolated from TABs as previously described22 and used after 3–8 doubling passages. Peripheral blood mononuclear cells (PBMCs) were obtained from whole blood of healthy donors using Lymphoprep (Axis-Shield, Oslo, Norway) (see culture details in online supplementary methods).
In specific experiments, VSMCs were seeded in 12-well plates and cultured alone or with 0.5×106 PBMC/well. At the end of the co-culture period, PBMCs were isolated from supernatants by centrifugation. The underlying VSMCs were separately recovered after gentle treatment with EDTA (Versene, Life Technologies) to remove adherent PBMC.
Gene expression analysis
Total RNA was obtained from cultured arteries or cells and cDNA was obtained by reverse-transcription (see online supplementary methods). Specific pre-developed TaqMan probes from Applied Biosystems (TaqMan Gene Expression Assays) (see online supplementary table S3) were used for PCR amplification. Fluorescence was detected with ABI PRISM 7900 Hardware and results were analysed with the Sequence Detection Software V.2.3 (Applied Biosystems). Gene expression was normalised to the expression of the endogenous control GUSb using comparative ΔCt method.5–7 ,11 mRNA concentration was expressed in relative units with respect to GUSb expression.
CXCL9, CXCL10 and CXCL11 concentrations in supernatants were measured by immunoassay using Quantikine (R&D Systems).
STAT-1 and STAT-3 phosphorylation in cultured arteries
Lysates were obtained from cultured artery sections or VSMC and phospho-STAT-1/total STAT-1 and phosho-STAT-3/total STAT-3 were assessed by western blot (see online supplementary methods).
Immunohistochemistry and immunofluorescence staining
Detailed immunostaining of cultured temporal artery sections or VSMC, as well as primary and secondary antibodies used, are depicted in online supplementary methods.
PBMC chemotaxis was assessed using Boyden chambers with 5 μm pore polycarbonate filters (see specific details in online supplementary methods).
Cell adhesion assays
VSMCs were grown to confluence in 96-well plates and stimulated with recombinant IFNγ. After 24 h 7.5×104 PBMCs per well were added and incubated at 37°C for 30 min. Wells were gently rinsed with phosphate-buffered saline and cells were fixed and stained with 0.2% crystal violet in 20% methanol for 10 min. Plates were extensively washed and crystal violet was solubilised with 1% sodium dodecyl sulfate (50 μL/well). Optical density was assessed by spectrophotometry at 560 nm wavelength.
Student's t test, when applicable, or Mann–Whitney test was applied for independent or paired samples for statistical analysis using SPSS software, PASW V.18.0.
Clone A6, a neutralising human monoclonal antibody against IFNγ, recognises IFNγ in GCA lesions and interferes with IFNγ-mediated signalling
Since A6 was screened and selected by its potential to neutralise IFNγ in vitro, we assessed its ability to bind IFNγ expressed in GCA lesions. As shown in figure 1, biotinylated A6 antibody immunostained GCA-involved temporal artery sections, whereas immunostaining with biotinylated human IgG1 was negative. Moreover, immunostaining of non-inflamed temporal artery sections from a control individual was negative according to the absence of IFNγ expression in normal arteries.4 ,7
Temporal artery culture in 3-D matrix has been shown to be a suitable model to test the effects of easily diffusing molecules such as dexamethasone.7 However, it is not known whether complex molecules such as monoclonal antibodies are able to elicit biological responses in this system. To test this point, we investigated whether A6 was able to interfere with IFNγ-mediated signalling in cultured arteries by exploring the phosphorylation status of the transcription factors STAT-1 and STAT-3. As shown in figure 1E, F, normal arteries in culture had a remarkable constitutive expression and phosphorylation of STAT-3 but not STAT-1. Involved GCA arteries in culture had increased expression and phosphorylation of STAT-1 and decreased expression and phosphorylation of STAT-3 compared with cultured normal arteries. A6 antibody decreased expression and phosphorylation of STAT-1, whereas STAT-3 expression/phosphorylation was not substantially affected. Treatment with recombinant IFNγ strongly increased expression and phosphorylation of STAT-1.
Neutralising endogenous IFNγ production selectively downregulates CXCL9, CXCL10, CXCL11 chemokines and STAT-1 expression in cultured GCA arteries: adding exogenous IFNγ elicits opposite effects
We investigated the effects of neutralising IFNγ with A6 on the expression of a variety of candidate molecules relevant to the pathogenesis of vascular inflammation and remodelling in GCA.3 ,5 ,11 ,22–30 Molecules investigated included transcription factors involved in T-cell functional differentiation, proinflammatory cytokines, chemokines/chemokine receptors, adhesion molecules, growth factors, metalloproteinases and their natural inhibitors, and extracellular matrix proteins (table 1 and figure 2). Since the temporal artery culture conveys by itself a downregulation of IFNγ expression with respect to the original fresh arteries, which may have minimised these results,7 we sought to confirm the potential effects of IFNγ revealed by inhibition with A6 antibody by treating cultured GCA arteries with recombinant IFNγ.
Among the molecules tested, neutralising endogenous IFNγ with A6 mainly downregulated STAT-1 and chemokine CXCL9, CXCL10 and CXCL11 mRNAs (figure 2A). As shown in figure 2B, exposure of cultured GCA arteries to IFNγ elicited the expected opposite effects and induced strong expression of STAT-1 and chemokines CXCL9, CXCL10 and CXCL11 (figure 2B). CXCL9 and CXCL10 concentrations in the supernatant fluid were also reduced upon A6 antibody treatment and increased under exposure to recombinant IFNγ (figure 2C). Concentrations of CXCL11 were around the detection level and were not substantially modified by A6 antibody or recombinant IFNγ, suggesting that CXCL11 is not secreted or is retained in the extracellular matrix.
Table 1 shows the effect of blocking IFNγ with A6, as well as the effect of adding recombinant IFNγ on the additional molecules tested. Neutralising IFNγ with A6 tended to decrease HLA-DRA, TBX21, NOS-2, TNFα, IL-6, CCL2, CXCR3, intracellular adhesion molecule-1 (ICAM-1) and platelet-derived growth factor A mRNAs and, consistently, these tended to increase upon exposure to recombinant IFNγ. However, with the exception of TNFα, differences were not statistically significant, possibly due to the relatively low number of specimens analysed and the wide individual variability in expression of inflammatory products. Dexamethasone was able to markedly downregulate additional relevant molecules not influenced by A6 (table 1).
VSMCs contribute to chemokine production induced by IFNγ
Most of the effects of IFNγ have been investigated in T cells, monocytes and endothelial cells. To mimic vascular inflammatory infiltrates, we co-cultured PBMC from healthy donors with human temporal artery-derived VSMC, the main component of the arterial wall. Co-culture induced a variety of chemokines not only in PBMC but also in VSMC, indicating that VSMCs are an active source of chemokines in an inflammatory microenvironment (figure 3A). IFNγ was produced and secreted by PBMC, basally and in co-culture (see online supplementary figure S1). In accordance with the previous results, neutralising IFNγ with A6 strongly and selectively inhibited CXCL9, CXCL10 and CXCL11 chemokine expression by all cell types (figure 3A). A slight, non-significant, reduction in STAT-1 and adhesion molecule ICAM-1 was observed. No effects of A6 were observed on the expression of STAT-3, VCAM-1 or other chemokines tested in this multicellular system (figure 3A and online supplementary figure S2).
To confirm that VSMC are an important source of chemokines upon IFNγ influence, we exposed human temporal artery-derived VSMC to IFNγ, which elicited a remarkable increase in STAT-1 (figure 3B). An induction of CXCL9, CXCL10 and CXCL11 and upregulation of constitutive CCL2 was obtained, whereas expression of other chemokines related to Th1 responses (ie, CCL3, CCL4 or CCL5) or CXCL8 was not significantly induced (figure 3B). Promoter analysis (4 kb upstream and 1 kb downstream of the transcription initiating sequence) of chemokine genes was performed using Chip Bioinformatics Mapper (http://snpper.chip.org/mapper/mapper-main).31 The promoters of CXCL9, 10, and 11 as well as CCL2 shared ISRE sequences, whereas the remaining chemokines tested did not, supporting the exquisite sensitivity of these cytokines to IFNγ exposure. However, although IFNγ significantly upregulated constitutive CCL2 expression by cultured VSMC, A6 failed to downregulate CCL2 in multicellular systems such as PBMC/VSMC co-culture or whole GCA arteries where other inducers may be present (table 1 and figure 3A).
As previously demonstrated in other settings,18 ,32 ,33 IFNγ also upregulated STAT-1 and adhesion molecule ICAM-1 expression by cultured VSMC and induced a slight expression of VCAM-1 and STAT-3 (figure 3B).
We next cultured temporal artery-derived VSMC from 8 patients and 11 controls and investigated chemokine production at passage zero to avoid phenotypic changes induced by prolonged culture. As shown in figure 3C, patient-derived VSMC conserved IFNγ signature and expressed significantly higher mRNA concentrations of IFNγ-induced chemokine CXCL9 and a tendency to increased expression of CXCL10 and CCL2 than VSMC derived from control individuals. Higher mRNA concentrations of other chemokines not clearly influenced by IFNγ in our experiments, particularly CCL4, were also observed. This may indicate VSMC exposure to stimuli other than IFNγ or to second-wave IFNγ-induced mediators in the complex multicellular and multimolecular microenvironment existing in GCA lesions.
Functional relevance of chemokine and adhesion molecule expression by VSMC
Treatment of cultured temporal artery-derived VSMC with IFNγ resulted in an increase in adhesion to PBMC (figure 4A).
The effect of IFNγ on ICAM-1 expression by VSMC was confirmed in GCA lesions. VSMC expressed ICAM-1 in cultured GCA arteries, particularly in the vicinity of inflammatory infiltrates. ICAM-1 expression was reduced in sections treated with A6 antibody and increased in sections treated with IFNγ (figure 4B). As already described,25 ICAM-1 expression was also observed in vasa vasorum endothelial cells and inflammatory cells (figure 4B).
Chemokine-rich supernatant of VSMC exposed to IFNγ stimulated PBMC chemotaxis in Boyden chambers (figure 4C), and this increase was abrogated by an antagonist of CXCR3, chemokine receptor common to CCL9, CXCL10 and CXCL11.
Effects of IFNγ neutralisation on infiltrating mononuclear cells in cultured temporal arteries from patients with GCA
The above findings suggest an important role for IFNγ in the initial recruitment of inflammatory cells in temporal arteries from patients with GCA and the participation of VSMC, the major component of normal arteries in this process. To confirm this hypothesis, normal temporal arteries were exposed to recombinant IFNγ and induction of CXCL9, CXCL10 and CXCL11 was confirmed (figure 5A). Incubation of IFNγ-treated normal arteries with PBMC from healthy donors resulted in infiltration of the artery wall by CD68 macrophages, which formed aggregates resembling giant cells (figure 5B). No CD3-positive cells penetrated the artery walls.
We next exposed cultured temporal arteries from patients with GCA to A6 and explored changes in the number of infiltrating T cells (CD3) and macrophages (CD68). Blocking IFNγ did not decrease the number of T cells (data not shown) but reduced the number of CD68-expressing cells and abrogated the presence of giant cells (figures 5C, D).
In this study, the first attempt to investigate the functional role of IFNγ in GCA, blocking endogenous IFNγ with a neutralising anti-IFNγ antibody, led to a significant reduction of STAT-1 and chemokine CXCL9, CXCL10 and CXCL11 expression in ex vivo cultured GCA arteries. Moreover, neutralising IFNγ resulted in decreased infiltration by CD68-expressing macrophages and reduced expression of TNFα along with a non-significant trend to decrease inflammatory molecules typical of a proinflammatory (M1-like) phenotype (HLA-DRA and inducible nitric oxide synthase).20 These molecules, previously known to be expressed in GCA, are modulated by IFNγ in other settings.5 ,19 ,20 ,23 ,26 Treatment of GCA arteries with exogenous IFNγ elicited opposite effects and tendencies, supporting the specificity of these findings.
Blocking IFNγ in our system led to a highly selective inhibition of ISRE-containing chemokine genes CXCL 9, 10 and 11. Although IFNγ also induced ISRE-dependent CCL2 in isolated VSMC, the effect of blocking IFNγ on CCL2 expression in GCA arteries was not apparent probably due to the remarkable constitutive expression of CCL2 in aged temporal arteries and the presence of potential additional inducers.34 Since CXCL 9, 10 and 11 are powerful chemoattractants of mononuclear cells and these are able to interact with ICAM-1 expressing microvessels in inflamed arteries, our findings support a relevant role for IFNγ in the development and perpetuation of inflammatory infiltrates.
Based on the potent known effects of IFNγ on macrophages, and their predominance in GCA lesions, we expected that blocking IFNγ would have higher impact in the expression of downstream macrophage inflammatory products such as HLA-DR, NOS-2 and monokines.20 In our model, IFNγ neutralisation slightly modified or did not modify at all a number of relevant proinflammatory molecules that were, indeed, suppressed by GC. This may be determined by concomitant activation of IFNγ-independent pathways. In this regard, neutralisation of IFNγ did not substantially reduce expression and activation of STAT-3, which appears to be highly activated in normal arteries and in GCA lesions, in accordance with the remarkable production of IL-6 in normal and inflamed arteries.4–6 Concomitant activation of STAT-3 and nuclear factor-κB may sustain expression of many inflammatory molecules in spite of IFNγ blockade.35–37
Most of the studies investigating IFNγ proinflammatory functions have explored its effects on macrophages and endothelial cells.18 ,33 In vascular biology, the effects of IFNγ have been essentially investigated in the setting of atherosclerosis and graft vasculopathy.38 ,39 In these models, IFNγ is expressed in lesions and production of IFNγ induced chemokines have been attributed to endothelial cells and inflammatory cells and only occasionally related to myofibroblasts.38 In VSMC, the effects of IFNγ have been mainly related to vascular remodelling and neointima formation.39 In recent years, it has become apparent that VSMC may acquire a strong proinflammatory phenotype in the appropriate context.40 ,41 Our findings indicate that, in GCA, VSMC are also important targets for IFNγ, which renders them active producers of chemokines and adhesion molecules, especially ICAM-1. Consequently, VSMCs likely contribute to the progression of inflammatory infiltrates through the medial layer of the artery wall and to the development of full-blown granulomatous lesions in GCA.
GC, the cornerstone of current GCA treatment, rapidly downregulate the expression of a variety of inflammatory cytokines (ie, IL-1β, TNFα, IL-6, IL-17), adhesion molecules (ie, ICAM-1) and matrix metalloproteinases (ie, MMP-9).7 ,11 ,27 ,28 However, GC do not repress IFNγ transcription.35 Although prolonged GC treatment eventually results in decreased IFNγ expression by other mechanisms,11 ,42–44 acute GC effects on IFNγ expression in GCA lesions are less dramatic than that observed with other cytokines.7 ,27 ,35 This has led to the hypothesis that incomplete suppression of IFNγ accounts for GCA relapses during GC tapering or withdrawal,29 and IFNγ has been considered a potential therapeutic target.29 ,35 However, our findings indicate that reducing STAT-1 expression and activation by blocking IFNγ may not be sufficient to abrogate inflammatory activity in full-blown GCA lesions, which may require blockade of multiple pathways. However, interfering with IFNγ might be useful in preventing relapses, given the relevant role of IFNγ in the recruitment of inflammatory cells since the very early inflammatory stages.11 ,45
In considering IFNγ as a potential therapeutic target, it is important to consider that IFNγ may have a protective role by limiting tissue injury.16 ,46 Blocking IFNγ worsens, indeed, experimental arthritis by promoting Th17 differentiation and exacerbation of IL-17-mediated inflammatory responses.47 In addition, an infectious trigger of GCA has been postulated, although no causative agents have been consistently identified.48 In this regard, IFNγ-deficient mice infected with murine herpesvirus HV68 develop necrotising large-vessel vasculitis, supporting the well-known role of IFNγ in host defence against viruses but also suggesting a role in limiting vascular injury.46 ,49 Moreover, in some experimental settings, but not in others, IFNγ deficiency exacerbates aortic aneurysm development, which is one of the important delayed complications of GCA.50–56
Our study has several limitations. On the one hand, it explores functional activities of IFNγ in a target organ isolated from a functional immune system and variations in chemokine and adhesion molecule expression could not result in effective changes in leucocyte recruitment. It is likely that, in vivo, inhibition of lymphocyte and monocyte recruitment and subsequent macrophage activation would result in greater impact on the generation of downstream inflammatory products. In addition, as mentioned, the culture itself downregulates IFNγ expression,7 which may have minimised the effect of IFNγ neutralisation in our model. GC treatment of some patients prior to the TAB may also have influenced results.7
In spite of these limitations, our findings indicate an important role for IFNγ in the recruitment and activation of macrophages, which may sustain and amplify subsequent waves of proinflammatory cascades in GCA. Moreover, our findings support the suitability of the temporal artery culture model to test functional activities not only of pharmacological agents or chemicals but also of complex molecules such as biological agents.
Handling editor Tore K Kvien
Contributors MCC and MC-B designed the study. MHK-V and J-MD contributed important input to its design. MC-B, EP-R, EL and NT performed the experimental work. MAA, SP-G, AG-M, GE-F and JH-R contributed to clinical selection and contributed to the experimental work. RA and AE supervised in silico promoter regions studies. All authors evaluated and criticised the data and PR-L and MHK-V provided important contributions to their interpretation. MC-B and MCC wrote the manuscript. All authors read, made improvements and approved the final version.
Funding Supported by Ministerio de Economía y Competitividad (SAF 11/30073 and SAF 14/57708-R) and by Instituto de Salud Carlos III (PIE13/00033) and Fondo europeo de Desarrollo Regional (FEDER)
Competing interests MHK-V and WGF are full employees by Novimmune. MCC, J-HR, GE-F and SP-G are currently participating in a clinical trial of tocilizumab (anti-IL-6R) in giant cell arteritis sponsored by Hoffmann-La Roche.
Patient consent Obtained.
Ethics approval Ethics committee of Hospital Clínic of Barcelona.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.